How to dose and monitor argatroban for treatment of HIT.

Abstract

Dosing and monitoring of argatroban for treatment of heparin-induced thrombocytopenia (HIT) remain uncertain. Marchetti and colleagues critically and systematically reviewed their institutional experience using this direct thrombin inhibitor to treat patients with laboratory-confirmed HIT, and have formulated several practical recommendations for managing this challenging clinical situation. Commentary on: Marchetti et al. Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia. Br J Haematol. 2022;197:766-790.

• Authors: Theodore E Warkentin
• Journal: British journal of haematology (Br J Haematol) Vol. 197 Issue 6 Pg. 653-655 (06 2022) ISSN: 1365-2141 [Electronic] England
• PMID: 35405030 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Anticoagulants
• Pipecolic Acids
• Sulfonamides
• Heparin
• Arginine
• argatroban

Topics

• Anticoagulants (therapeutic use)
• Arginine (analogs & derivatives)
• Heparin (therapeutic use)
• Humans
• Pipecolic Acids (pharmacology)
• Retrospective Studies
• Sulfonamides
• Thrombocytopenia (chemically induced, drug therapy)